THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [6.11]-C42 ID: TIP-MED-000312

Tamoxifen Citrate

Active Ingredient / Scientific Identity: Tamoxifen Citrate • Class: Third-Generation Aromatase Inhibitor & Selective Estrogen Receptor Modulators (SERMs) (Schedule H | NLEM 2022)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Tamoxifen Citrate ([6.11]-C42 | ID: TIP-MED-000312) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/6-11-c42-tamoxifen-citrate/
Generic / Entity NameTamoxifen Citrate ([6.11]-C42)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassThird-Generation Aromatase Inhibitor & Selective Estrogen Receptor Modulators (SERMs) (Sch
Available Dosage FormsLetrozole Tablets: 2.5 mg, 5 mg. Clomiphene Tablets: 25 mg, 50 mg, 100 mg. Tamoxifen Tablets: 10 mg, 20 mg
Regulatory ClassificationSchedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this pre
Key Warning & Review DateRenal: No adjustment needed if CrCl >10 mL/min. Hepatic: Halve Letrozole frequency (2.5 mg alternate days) in Child–Pugh C ci
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H & Schedule G Prescription Drug ('Caution:✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Tamoxifen Citrate (TIP-MED-000312, Reference Code [6.11]-C42) is classified under Thyroid, Pituitary, Adrenal & Hormonal Medicines (Ch 06) as a Third-Generation Aromatase Inhibitor & Selective Estrogen Receptor Modulators (SERMs) (Schedule H | NLEM 2022). Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [6.11] (Letrozole, Clomiphene Citrate & Tamoxifen Citrate). Representative Indian Market Examples (Edition 2.7 Ch 06 [6.11], p. 77): Letrozole: Letroz (Sun), Fempro (Cipla), Femara (Novartis). Clomiphene: Clome (Abbott), Fertomid (Cipla), Siphene (Serum). Tamoxifen: Tamodex (Biochem), Mamofen (Khandelwal), Nolvadex — Strengths & Dosage Forms: Letrozole Tablets: 2.5 mg, 5 mg. Clomiphene Tablets: 25 mg, 50 mg, 100 mg. Tamoxifen Tablets: 10 mg, 20 mg
Co-indexed constituent under primary monograph [6.11] (Letrozole, Clomiphene Citrate & Tamoxifen Citrate). Representative Indian Market Examples (Edition 2.7 Ch 06 [6.11], p. 77): Letrozole: Letroz (Sun), Fempro (Cipla), Femara (Novartis). Clomiphene: Clome (Abbott), Fertomid (Cipla), Siphene (Serum). Tamoxifen: Tamodex (Biochem), Mamofen (Khandelwal), Nolvadex — Strengths & Dosage Forms: Letrozole Tablets: 2.5 mg, 5 mg. Clomiphene Tablets: 25 mg, 50 mg, 100 mg. Tamoxifen Tablets: 10 mg, 20 mg
Dosage Forms & Available Strengths:
Letrozole Tablets: 2.5 mg, 5 mg. Clomiphene Tablets: 25 mg, 50 mg, 100 mg. Tamoxifen Tablets: 10 mg, 20 mg
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Third-Generation Aromatase Inhibitor & Selective Estrogen Receptor Modulators (SERMs) (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Thyroid, Pituitary, Adrenal & Hormonal Medicines (Ch 06): clinical efficacy is mediated via Third-Generation Aromatase Inhibitor & Selective Estrogen Receptor Modulators (SERMs) (Schedule H | NLEM 2022) for Letrozole: First-line ovulation induction in PCOS infertility; adjuvant/metastatic ER-positive postmenopausal breast cancer. Clomiphene: Ovulation induction in anovulatory infertility. Tamoxifen: ER-positive pre- and postmenopausal breast cancer, gynaecomastia, idiopathic oligozoospermia.

4. Therapeutic Indications & Evidence-Supported Uses

  • Letrozole: First-line ovulation induction in PCOS infertility
  • adjuvant/metastatic ER-positive postmenopausal breast cancer
  • Clomiphene: Ovulation induction in anovulatory infertility
  • Tamoxifen: ER-positive pre- and postmenopausal breast cancer, gynaecomastia, idiopathic oligozoospermia

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Ovulation Induction: Letrozole 2.5–5 mg PO OD from Cycle Day 2–6 (or Day 3–7) for 5 days; OR Clomiphene 50–100 mg PO OD from Cycle Day 2–6 for 5 days (Max 3–6 cycles). Breast Cancer: Letrozole 2.5 mg PO OD for 5–10 years; Tamoxifen 20 mg PO OD for 5–10 years

Administration & Meal Timing: May be taken with or without food | Morning (Once Daily; for ovulation induction, strictly on the 5 prescribed cycle days ONLY!)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [6.11].
Metabolism & Biotransformation:
Renal: No adjustment needed if CrCl >10 mL/min. Hepatic: Halve Letrozole frequency (2.5 mg alternate days) in Child–Pugh C cirrhosis; Clomiphene contraindicated in liver disease
Elimination & Renal Adjustment:
Renal: No adjustment needed if CrCl >10 mL/min. Hepatic: Halve Letrozole frequency (2.5 mg alternate days) in Child–Pugh C cirrhosis; Clomiphene contraindicated in liver disease
Hepatic Impairment Considerations:
Renal: No adjustment needed if CrCl >10 mL/min. Hepatic: Halve Letrozole frequency (2.5 mg alternate days) in Child–Pugh C cirrhosis; Clomiphene contraindicated in liver disease

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • CONTRAINDICATIONS: Pregnancy (ALWAYS exclude pregnancy before starting a new 5-day ovulation-induction cycle — Letrozole & Clomiphene are teratogenic if taken after conception!), undiagnosed vaginal bleeding, ovarian cysts (non-PCOS), and severe liver disease

Key Clinical Precautions: Renal: No adjustment needed if CrCl >10 mL/min. Hepatic: Halve Letrozole frequency (2.5 mg alternate days) in Child–Pugh C cirrhosis; Clomiphene contraindicated in liver disease

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Hot flushes, night sweats, headache, fatigue; Letrozole (long-term oncology): Arthralgia/myalgia, bone mineral density loss; Clomiphene: Pelvic fullness, multiple gestation (twins 5–8%), visual blurring/scotomas
  • Ovarian Hyperstimulation Syndrome (OHSS — rapid abdominal bloating, weight gain, oliguria, dyspnoea -> emergency!), Tamoxifen-induced Endometrial Hyperplasia/Carcinoma and Venous Thromboembolism (DVT/PE), Clomiphene visual disturbances (stop drug immediately and permanently!)
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • CRITICAL TAMOXIFEN INTERACTION: Tamoxifen is a prodrug requiring hepatic CYP2D6 conversion to active Endoxifen — POTENT CYP2D6 INHIBITORS (Fluoxetine, Paroxetine, Bupropion, Cinacalcet) block Endoxifen formation and increase breast cancer recurrence! (Prefer Venlafaxine or Escitalopram if an antidepressant is needed with Tamoxifen!)
    • Tamoxifen potentiates Warfarin markedly

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [6.11].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: For fertility patients: take ONLY for the 5 days prescribed (e.g., Day 2 to Day 6 of period) and never take if already pregnant; for Clomiphene: stop immediately if blurry vision or flashes occur; for Tamoxifen: report any postmenopausal vaginal spotting or leg swelling immediately
    • Meal & Clock Timing Instruction: May be taken with or without food (Morning (Once Daily; for ovulation induction, strictly on the 5 prescribed cycle days ONLY!))
    • Missed Dose Protocol: Take same day if remembered; in 5-day fertility regimens, contact gynaecologist if a cycle day is missed
    • Geriatric Dispensing Pearl: Monitor bone density (DEXA) and fracture risk in older women on adjuvant Letrozole

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Letrozole Tablets: 2.5 mg, 5 mg. Clomiphene Tablets: 25 mg, 50 mg, 100 mg. Tamoxifen Tablets: 10 mg, 20 mg

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

    ← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
    Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/6-11-c42-tamoxifen-citrate/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.